These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 20964835

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ, El Mashad SM, O'Donovan TR, Ahmad S, Collins C, Sweeney P, Rogers E, O'Sullivan GC, McKenna SL.
    Anal Cell Pathol (Amst); 2010; 33(3):121-32. PubMed ID: 20978319
    [Abstract] [Full Text] [Related]

  • 4. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ, El Mashad SM, O'Donovan TR, Ahmad S, Collins C, Sweeney P, Rogers E, O'Sullivan GC, McKenna SL.
    Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
    [Abstract] [Full Text] [Related]

  • 5. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
    Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S.
    Clin Cancer Res; 2013 Sep 15; 19(18):5218-26. PubMed ID: 23881929
    [Abstract] [Full Text] [Related]

  • 6. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
    Gong K, Zhang N, Zhang K, Na Y.
    Int J Mol Med; 2010 Dec 15; 26(6):907-12. PubMed ID: 21042786
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.
    Ashida S, Nishimori I, Tanimura M, Onishi S, Shuin T.
    J Cancer Res Clin Oncol; 2002 Oct 15; 128(10):561-8. PubMed ID: 12384800
    [Abstract] [Full Text] [Related]

  • 13. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
    Ordóñez-Navadijo Á, Fuertes-Yebra E, Acosta-Iborra B, Balsa E, Elorza A, Aragonés J, Landazuri MO.
    Oncogene; 2016 Feb 04; 35(5):587-94. PubMed ID: 25915846
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
    Fan Y, Li H, Ma X, Gao Y, Bao X, Du Q, Ma M, Liu K, Yao Y, Huang Q, Zhang Y, Zhang X.
    Oncotarget; 2016 Apr 05; 7(14):18280-94. PubMed ID: 26943772
    [Abstract] [Full Text] [Related]

  • 19. Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells.
    Harten SK, Esteban MA, Shukla D, Ashcroft M, Maxwell PH.
    Mol Cancer; 2011 Jul 26; 10():89. PubMed ID: 21791076
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.